Skip to main content

Kyntra Bio, Inc.

KYNB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000921299

No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Kyntra Bio, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of KYNB: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders110100−10
Shares68.3M70.1M+1.74M (+2.5%)
Value$59.0M$62.1M+$3.15M (+5.3%)

New holders (12)

Institutions that held Kyntra Bio, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to KYNB in Q4 2023
InstitutionSharesValue% of portfolio
Pennant Investors, LP768,400$681.0K0.21%
683 Capital Management, LLC700,254$620.6K0.06%
Lighthouse Investment Partners, LLC153,764$136.3K0.01%
Deutsche Bank AG95,284$84.8K0.00%
Wexford Capital LP32,190$28.5K0.01%
State Board of Administration of Florida Retirement System23,988$21.3K0.00%
BBR Partners, LLC16,444$14.6K0.00%
Janney Montgomery Scott LLC14,000$12.0K0.00%
Nixon Capital, LLC7,274$6.45K0.00%
EverSource Wealth Advisors, LLC734$6510.00%
Qube Research & Technologies Ltd379$3360.00%
Nisa Investment Advisors, LLC100$890.00%

Sold out (22)

Institutions that held Kyntra Bio, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.